

January 24, 2020

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001

**The National Stock Exchange of India Limited**  
Exchange Plaza , Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051

Scrip code: 532531

Scrip code: STAR

Dear Sirs,

**Sub: Press Release**

Please find attached Press Release issued by the Company titled:

**‘Strides announces the successful completion of US FDA inspection  
at its Alathur facility with “Zero 483 observations”’**

Thanks & Regards,

**For Strides Pharma Science Limited**



**Manjula Ramamurthy**  
**Company Secretary**



*Encl: As Above*

**Strides Pharma Science Limited**

(Formerly Strides Shasun Limited)

CIN: L24230MH1990PLC057062

**Corp Off:** Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India

Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

**Regd Off:** 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India

Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

info@strides.com; www.strides.com

---

## Strides announces the successful completion of US FDA inspection at its Alathur facility with “Zero 483 observations”

### *Second consecutive Zero 483 inspection for the site*

---

**Bangalore, January 24, 2020** - Strides Pharma Science Limited (Strides) today announced that its formulation facility at Alathur (Chennai), India underwent a USFDA inspection which concluded with “Zero 483 observations”. This is the second consecutive Zero 483 inspection for the site. The current inspection was a Pre-Approval Inspection for sustained release class of drugs which is a new dosage format for the facility and is one of the focus areas for the company in the global markets.

The Alathur facility became part of the Strides manufacturing base in May 2017 after the Company entered into a 50:50 joint venture(JV) with Vivimed Labs. In March 2019, Strides converted its ownership in JV to 100% to take full management and operational control of this manufacturing facility. The facility recently completed a significant capacity expansion which will support the growth momentum for the US business

#### About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India- Bangalore (two locations), Pondicherry, and Chennai, Singapore, Italy- Milan, Kenya- Nairobi and United States-Florida. The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at [www.strides.com](http://www.strides.com)

#### **For further information, please contact:**

<p><b>Strides</b> <b>Badree Komandur</b> Executive Director - Finance +91 80 6784 0747</p> <p><b>Investor Relations:</b> <b>Kannan. N:</b> +91 98450 54745 <b>Vikesh Kumar:</b> +91 80 6784 0827 <b>Sandeep Baid:</b> +91 80 6784 0791 Email: <a href="mailto:Sandeep.baid@strides.com">Sandeep.baid@strides.com</a></p>	<p><b>PR Consultancy</b> Fortuna PR K Srinivas Reddy: +91 90005 27213 <a href="mailto:srinivas@fortunapr.com">srinivas@fortunapr.com</a></p> <p>K Priya: +91 95354 25418 <a href="mailto:priya@fortunapr.com">priya@fortunapr.com</a></p>
--	---

**Strides Pharma Science Limited**

(Formerly Strides Shasun Limited)

CIN: L24230MH1990PLC057062

Regd. Office: 201, 'Devavrata', Sector - 17,  
Vashi, Navi Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta  
Road, Bangalore – 560 076